WASHINGTON, Dec. 16, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today provided an update on its appeal of the recent HETLIOZ^® ANDA litigation ruling.

On December 14, 2022, Vanda appealed the December 13^th decision of the United States District Court for the District of Delaware in the HETLIOZ^® ANDA litigation to the United States Court of Appeals for the Federal Circuit and requested an injunction prohibiting market entry by Teva Pharmaceuticals USA, Inc. (Teva) and Apotex Inc. (Apotex) while the appeal is pending. Today, the Court granted a temporary injunction to prohibit market entry by Teva and Apotex until at least January 6, 2023 while the Court considers Vanda's pending motion for an injunction that would extend until the Court decides the appeal. 

Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com and follow us on Twitter @vandapharma.

For full U.S. Prescribing Information for HETLIOZ^® and HETLIOZ LQ^®, including indication and Important Safety Information, visit www.hetlioz.com.

Corporate Contact:
Kevin Moran
Senior Vice President, Chief Financial Officer and Treasurer 
Vanda Pharmaceuticals Inc.
202-734-3400
This email address is being protected from spambots. You need JavaScript enabled to view it.

Elizabeth Van Every
Head of Corporate Affairs
Vanda Pharmaceuticals Inc.
202-734-3400
This email address is being protected from spambots. You need JavaScript enabled to view it.